 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MedSpray's patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer's disease, and anorexia...

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for...

Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate

Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trialENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO...

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Human tissue study assessed SPU-21's efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ( the Company...

Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Silo Pharma, Inc. (NASDAQ:SILO  Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 82,100...

Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Decreases By 14.6%

Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ( the...

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq...

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Laidlaw assumed coverage on shares of Silo Pharma (NASDAQ:SILO  Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a...

Silo Pharma (NASDAQ:SILO) Receives New Coverage from Analysts at Laidlaw

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Silo Pharma initiated with a Buy at Laidlaw

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.

Market Cap	$4.63M
Volume (M)	28,548.00
52-Wk High	$6.56
52-Wk Low	$1.22

Current Price	$1.49
Prev Close	$1.48
Open	$1.47
Dividend Yield	0.00%
50-Day Moving Average	$1.51
Beta	0.09
Avg. Volume	235,092.86
PE Ratio	-1.11

52-Week High	$6.56
52-Week Low	$1.22
Market Capitalization	$4.63M
EPS	-$1.35
Price to Book	0.62
Revenue Per Employee	$24,034.00
Enterprise Value/EBITDA	0.82

SILO Silo Pharma Inc

About

Feed

News

Fundamentals